OPZELURA cream (ruxolitinib 1.5%) is a topical JAK inhibitor and the first targeted therapy approved for vitiligo. It was authorized for nonsegmental vitiligo in patients aged 12 and older in the U.S. in July 2022 and in Europe in April 2023.
Vitiligo is an autoimmune disease in which T cells attack melanocytes. When T cells that have accumulated in the skin release interferon-gamma, nearby skin cells produce chemokines such as CXCL10 via intracellular JAK signaling, and these chemokines recruit more T cells to the skin. Applying OPZELURA inhibits JAK1 and JAK2 at the site, reducing chemokine production and weakening the immune attack on melanocytes. However, in older lesions where melanocytes have been completely lost, immune modulation alone may not be sufficient to restore pigment.
